Showing 3441-3450 of 5773 results for "".
- Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-receives-fda-clearance-of-ind-application-for-atsn-201-an-investigational-gene-therapy-for-the-treatment-of-x-linked-retinoschisis/2481580/Atsena Therapeutics, a clinical-stage gene therapy company, announced the FDA has cleared the company’s investigational new drug (IND) application for a phase 1/2 clinical trial of ATSN-201 in patients with X-linked retinoschisis (XLRS). ATSN-201 leverages one of the company&rsquo
- VMG Health Acquires Healthcare Consulting Firm BSM Consultinghttps://modernod.com/news/vmg-health-acquires-healthcare-consulting-firm-bsm-consulting/2481579/VMG Health announced it has acquired BSM Consulting, a health care consulting firm with offices in Reno, Nevada and Phoenix. Financial terms of the acquisition were not disclosed. VMG Health is owned by VMG employees and Northlane Capital Partners (NCP). NCP inv
- Glaukos Featured in Numerous Scientific Abstracts at the 2023 ASCRS Meetinghttps://modernod.com/news/glaukos-featured-in-numerous-scientific-abstracts-at-the-2023-ascrs-meeting/2481578/Glaukos announced that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held May 5–8, 2023 in San Diego. Glaukos will be exhibiting onsite at booth #1237. Key Glaucoma Prese
- Japanese Drugmaker Astellas Pharma Acquires Iveric Bio for $5.9 Billionhttps://modernod.com/news/japanese-drugmaker-astellas-pharma-acquires-iveric-bio-for-59-billion-1/2481577/Japan-based Astellas Pharma announced it is acquiring Iveric Bio, maker of a geographic atrophy drug in late-stage development, for $5.9 billion. Under terms of the agreement, the companies entered into a definitive agreement under which Berry Merger Sub Inc., a wholly-owned subsidiary
- Ocumension Therapeutics Receives Priority Review Status for Zerviate New Drug Application in Chinahttps://modernod.com/news/ocumension-therapeutics-receives-priority-review-status-for-zerviate-new-drug-application-in-china/2481575/Nicox SA announced that the new drug application (NDA) for approval to commercialize Zerviate (cetirizine ophthalmic solution) 0.24%, submitted in China by its exclusive Chinese partner, Ocumension Therapeutics, has been included in the priority review and approval process of Natio
- Johnson & Johnson Vision Receives FDA Clearance for its Elita Femtosecond Laserhttps://modernod.com/news/johnson-johnson-vision-receives-fda-clearance-for-its-elita-femtosecond-laser/2481573/Johnson & Johnson Vision announced that it has received FDA 510(k) clearance for the Elita Femtosecond Laser for the creation of LASIK flaps. Elita will be unveiled at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) in San Diego, May 5-8
- EssilorLuxottica Unveils 4-Year Clinical Trial Results of its Essilor Stellest Lens athttps://modernod.com/news/essilorluxottica-unveils-4-year-clinical-trial-results-of-its-essilor-stellest-lens-at-arvo-at/2481572/EssilorLuxottica presented the 4-year clinical trial results of its Essilor Stellest lens for myopia control at the 2023 ARVO annual meeting in New Orleans. The findings show that Essilor Stellest lenses continue to exhibit strong efficacy in slowing myopia progression and axial ey
- Lumibird Launches Tango Neo and UltraQ Reflex Neo Lasershttps://modernod.com/news/lumibird-launches-tango-neo-and-ultraq-reflex-neo-lasers/2481570/Following the launch of its flagship product, the Tango Reflex Neo, in December 2022, Lumibird Medical announced the launch of two additional variants within its premium Nd:YAG/SLT laser range—the UltraQ Reflex Neo and Tango Neo. A fully integrated Q-switched Nd:YAG lase
- RG6501 (OpRegen) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in GAhttps://modernod.com/news/rg6501-opregen-phase-12a-clinical-results-support-the-potential-for-opregen-to-slow-stop-or-reverse-disease-progression-in-ga/2481569/Lineage Cell Therapeutics announced that results from imaging analyses of structural changes and visual data from a phase 1/2a clinical study of RG6501 (OpRegen), were presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2023). The presentation
- Registration Now Open for Neuro-Optometric Rehabiliation Association 2023 Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabiliation-association-2023-conference/2481568/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) 33rd annual conference, October 5-8, at the Portland Marriot Downtown Waterfront in Portland, Oregon. The NORA annual conference is an event for eye care and other health care